Invention Grant
- Patent Title: Quinolinyl glucagon receptor modulators
- Patent Title (中): 喹啉基胰高血糖素受体调节剂
-
Application No.: US14232379Application Date: 2012-07-12
-
Publication No.: US08927577B2Publication Date: 2015-01-06
- Inventor: Mary Didiuk , Kevin J. Filipski , Angel Guzman-Perez , Esther C. Lee , Jeffrey A. Pfefferkorn , Benjamin Stevens , Meihua Tu
- Applicant: Mary Didiuk , Kevin J. Filipski , Angel Guzman-Perez , Esther C. Lee , Jeffrey A. Pfefferkorn , Benjamin Stevens , Meihua Tu
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agent James T. Wasicak
- International Application: PCT/IB2012/053575 WO 20120712
- International Announcement: WO2013/014569 WO 20130131
- Main IPC: C07D215/38
- IPC: C07D215/38 ; C07D239/94 ; A61K31/47 ; A61K31/502 ; A61P3/10 ; C07D241/44 ; C07D217/22 ; C07D239/84

Abstract:
The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
Public/Granted literature
- US20140135338A1 QUINOLINYL GLUCAGON RECEPTOR MODULATORS Public/Granted day:2014-05-15
Information query